این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
صفحه اصلی
درباره پایگاه
فهرست سامانه ها
الزامات سامانه ها
فهرست سازمانی
تماس با ما
JCR 2016
جستجوی مقالات
دوشنبه 5 آبان 1404
Iranian Journal of Public Health
، جلد ۵۳، شماره ۸، صفحات ۱۷۵۴-۱۷۶۸
عنوان فارسی
چکیده فارسی مقاله
کلیدواژههای فارسی مقاله
عنوان انگلیسی
Effect on Non-Small Cell Lung Cancer After Combination of Driver Gene Mutations and Anti-PD -1/PD-L1 Immunotherapy as Well as Chemotherapy
چکیده انگلیسی مقاله
Background: We aimed to reveal the correlation between pathological indicators and PD-L1, between gene mutation status in lung cancer through clinico-pathological data and lung cancer-related gene mutation and PD-L1 expression analysis. Methods: The study was conducted in . PD-L1 testing and targeted gene mutations detection were evaluated. The clinical characteristics of these non-small cell lung cancer (NSCLC) samples have been obtained. The groups were grouped according to clinico-pathological features and PD-L1 expression (Yes/No or High/Low), and the clinico-pathological and genetic and molecular features and correlation with PD-L1 expression were compared across the above groups. Comparisons and analyses were made between different treatment schemes. Results: Lung adenocarcinoma (LUAD, n=142) and lung squamous carcinoma (LUSC, n=143) samples were enrolled (median age: 64 years old). Pleural invasion and M staging were significantly different from PD-L1 alterations (P<0.05). The percentage of patients with PD-L1 tumor proportion score (TPS)≥50% was 36.24% and the percentage of patients with PD-L1 TPS<50% was 29.53%. The percentage of patients with PD-L1 high-expressed and treated by immunotherapy was 75.93% and 63.41% experienced Partial Response/Complete Response. The mutations ratio of EGFR, ALK, KRAS, MET, RET and TP53 were 28.86%, 1.34%, 6.04%, 0.67%, 1.34% and 0.67%, respectively. KRAS mutation was significantly different from PD-L1 alterations (P<0.01). Conclusion: There are individual differences in PD-L1 expression, which can also vary depending on the different clinical features. Specific molecular features correlate with differential PD-L1 expression and may influence the response to therapy.
کلیدواژههای انگلیسی مقاله
نویسندگان مقاله
| Zhengming Huang
Pulmonary and Critical Care Medicine, Jinhua Municipal Central Hospital, Zhejiang University, Zhejiang, China
| Long Yu
Pulmonary and Critical Care Medicine, Jinhua Municipal Central Hospital, Zhejiang University, Zhejiang, China
| Weisong Chen
Pulmonary and Critical Care Medicine, Jinhua Municipal Central Hospital, Zhejiang University, Zhejiang, China
| Dan Zhu
Pulmonary and Critical Care Medicine, Jinhua Municipal Central Hospital, Zhejiang University, Zhejiang, China
| Hui Chen
Pulmonary and Critical Care Medicine, Jinhua Municipal Central Hospital, Zhejiang University, Zhejiang, China
نشانی اینترنتی
https://ijph.tums.ac.ir/index.php/ijph/article/view/33366
فایل مقاله
فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به:
صفحه اول پایگاه
|
نسخه مرتبط
|
نشریه مرتبط
|
فهرست نشریات